Biotech News
Related news
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-05-05 11:00 EST
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
SPROSpero Therapeutics2026-03-18 16:05 EST
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
ENTAEnanta Pharmaceuticals2026-08-10 20:01 EST
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
VIRIVirios Therapeutics2026-03-18 12:30 EST
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ANTXAN2 Therapeutics2026-03-17 20:00 EST
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
IMNNImunon2026-08-04 12:00 EST
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026
IMNNImunon2026-05-05 12:30 EST
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
ABUSArbutus2026-03-23 11:30 EST
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Atea
Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...
Recent company news
AVIRAtea2026-09-08 11:00 EST
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
AVIRAtea2026-08-12 20:05 EST
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
AVIRAtea2026-08-05 11:00 EST
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
AVIRAtea2026-07-28 11:00 EST
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Stock data
- Close
- 5.26 USD
- Market cap
- 341.72M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States